Abstract
The radioisotope99mTc, used in greater than 80% of nuclear medicine applications, has traditionally been produced and supplied to radiopharmaceutical companies in the form of its precursor99Mo. Nuclear fission produced99Mo had been supplied by Nordion International of Canada and Cintichem, Inc. of New York, USA. With the shutdown of Cintichem's reactor in 1989, a need was recognized for a US supply, and the US Department of Energy recently published a record of decision designating Sandia National Laboratories (SNL) to meet that need. A recent campaign was launched which utilized the SNL Annular Core Research Reactor to irradiate UO2 coated targets fabricated by Los Alamos National Laboratory to produce99Mo. The irradiated targets were chemically processed in the SNL Hot Cell Facility to separate and purify the99Mo. The campaign also included final product quality analysis, and process waste handling. The campaign was accomplished with high99Mo recovery. Final product quality was assessed at SNL, and samples were sent to an outside laboratory for independent verification. The campaign provided data and experience useful in pursuing US Food and Drug Administration and radiopharmaceutical company approval.
Similar content being viewed by others
References
M. A. Langton, Trans. Am. Nucl. Soc., 72 (1995) 134.
R. L. Coats, Trans. Am. Nucl. Soc., 72 (1995) 141.
E. J. Parma. Trans. Amer. Nucl. Soc., 73 (1995) 401.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Talley, D.G., Bourcier, S.C., McDonald, M.J. et al. Initial generation and separation of99Mo at Sandia National Laboratories. J Radioanal Nucl Chem 236, 169–173 (1998). https://doi.org/10.1007/BF02386337
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02386337